Magazine

Earning approval to use a new cardiovascular drug in the clinical setting can cost 100+ times the average of bringing other medications to market.  

Telehealth enthusiasts are optimistic about telestenting’s potential to solve access-to-care issues but concede that significant obstacles must be overcome before it will be ready for prime time.

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist. 

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR. 

The Heart Rhythm Society's 2019 scientific sessions will be held May 8-11 in San Francisco, a venue that enabled the program committee to tap into Silicon Valley’s expertise with digital health, emerging technology and innovation. HRS.19 Program Director Christine Albert, MD, MPH, gave Cardiovascular Business a preview of meeting highlights.

SCAI has diversified its planning committees and expanded the focus on live cases for its 2019 scientific sessions, says Program Chair Sunil Rao, MD.

Where I live in Pennsylvania, not far from the “Heroin Highway,” the local news delivers frequent but superficial glimpses of the impact of the opioid epidemic on families and our communities. Statistics underscore such stories: More than 70,000 drug over-dose deaths just in 2017 with an associated “economic burden” exceeding $78 billion per year. 

Receiving payments from industry influenced physicians’ device selection but not patient outcomes, according to researchers who analyzed three years of Open Payment Program data.

A new stem cell-based test may add certainty to efforts to predict whether so-called variants of uncertain significance will contribute to the development of diseases or be harmless. 

I don’t need to tell you that social determinants of health (SDoH) present challenges for your patients. You’ve seen the data indicating that as much as 80 percent of an individual’s health comes from factors other than the clinical care he or she receives. You know the impact of disparities. 

ACC.19 will feature 36 late-breaking clinical trials and clinical research studies, starting with the Apple Heart Study’s findings on the ability of a smartwatch to help identify atrial fibrillation. That question is just one of many the conference will address, says ACC.19 Program Chair Andrew Kates, MD, professor of medicine and director of the cardiology fellowship program at Washington University School of Medicine in St. Louis. During a conversation with Cardiovascular Business, Kates predicted trial highlights and previewed some ACC.19 program innovations. 

Coronary artery calcium scanning is not a Magic 8 Ball, but it is a powerful predictor and a valuable tool for cardiology practices.

Select an Issues